Chemotherapy: How It Works and What to Expect

Chemotherapy is one of the most widely used systemic cancer treatments, employing chemical agents to destroy or inhibit the growth of malignant cells throughout the body. This page covers the biological mechanisms behind chemotherapy, the major drug classes involved, common clinical scenarios in which it is prescribed, and the factors that guide treatment decisions. Understanding these elements helps patients and caregivers interpret treatment plans within the broader landscape of oncology.

Definition and scope

Chemotherapy refers to the use of cytotoxic or cytostatic pharmaceutical agents to treat cancer by targeting rapidly dividing cells. The U.S. Food and Drug Administration (FDA) regulates the approval of all chemotherapy agents, evaluating efficacy and safety data before a drug enters clinical use. The National Cancer Institute (NCI) classifies chemotherapy as a systemic treatment, meaning drugs circulate through the bloodstream and can reach cancer cells across the body — distinguishing it from localized approaches such as surgery or radiation.

Chemotherapy encompasses more than 100 individual approved drugs, grouped into distinct classes based on mechanism of action. It is administered through intravenous infusion, oral tablets, intramuscular injection, intrathecal delivery (directly into spinal fluid), or topical application, depending on the cancer type and treatment goal.

How it works

Chemotherapy agents interfere with the cell cycle — the sequence of phases a cell passes through to divide and reproduce. Because cancer cells divide more rapidly and with less regulatory control than most normal cells, they are disproportionately vulnerable to agents that disrupt this cycle. However, rapidly dividing normal cells — in bone marrow, the gastrointestinal lining, and hair follicles — are also affected, which accounts for the characteristic side effect profile.

The NCI organizes chemotherapy drugs into the following major mechanistic classes:

Alkylating agents (e.g., cyclophosphamide, cisplatin) — cross-link DNA strands, preventing replication. These are among the oldest class in clinical use.
Antimetabolites (e.g., methotrexate, 5-fluorouracil) — mimic natural cellular building blocks, disrupting DNA and RNA synthesis.
Topoisomerase inhibitors (e.g., irinotecan, etoposide) — block enzymes that manage DNA strand coiling during replication, causing lethal strand breaks.
Mitotic inhibitors (e.g., paclitaxel, vincristine) — interfere with the mitotic spindle, halting cell division at a specific phase.
Antitumor antibiotics (e.g., doxorubicin, bleomycin) — intercalate into DNA or generate free radicals that damage DNA structure.
Corticosteroids (e.g., prednisone, dexamethasone) — used adjunctively in certain hematologic malignancies and to manage treatment-related inflammation.

Each class carries a distinct toxicity profile. Anthracyclines such as doxorubicin carry a cumulative cardiotoxicity risk, with lifetime dose limits established to reduce cardiomyopathy incidence (NCI Drug Information). Platinum-based agents such as cisplatin are associated with nephrotoxicity and peripheral neuropathy.

Chemotherapy differs substantially from targeted therapy, which acts on specific molecular markers present on cancer cells, and from immunotherapy, which modulates the immune system rather than directly attacking tumor cells. Chemotherapy's mechanism is broadly cytotoxic rather than molecularly selective.

Common scenarios

Chemotherapy is used across a range of clinical contexts defined by treatment intent and timing relative to other interventions:

Curative intent — used as the primary treatment for cancers such as leukemia, lymphoma, and testicular cancer, where chemotherapy alone or in combination achieves complete remission in a substantial proportion of patients.
Neoadjuvant chemotherapy — administered before surgery to shrink a tumor, improving resectability. This approach is common in locally advanced breast cancer and bladder cancer.
Adjuvant chemotherapy — given after surgery to eliminate residual microscopic disease and reduce recurrence risk. The National Comprehensive Cancer Network (NCCN) publishes evidence-based guidelines specifying adjuvant chemotherapy recommendations by cancer type and stage.
Palliative chemotherapy — used in metastatic disease not amenable to cure, with the goal of controlling tumor growth, relieving symptoms, and extending survival rather than achieving remission. Palliative care principles are often integrated alongside this approach.
Concurrent chemoradiation — chemotherapy administered simultaneously with radiation therapy to sensitize tumor cells, a standard approach in head and neck cancers and cervical cancer.

The regulatory context for oncology determines which agents are approved for specific indications, and off-label use is governed by institutional protocols and payer policy.

Decision boundaries

The selection of a chemotherapy regimen depends on multiple converging factors evaluated by a medical oncologist:

Cancer type and histology — different malignancies respond to different drug classes; pathology confirmation via biopsy and molecular profiling informs regimen selection.
Stage and extent of disease — cancer staging determines whether systemic therapy is indicated and at what intensity.
Patient performance status — standardized scales such as the Eastern Cooperative Oncology Group (ECOG) Performance Status score (0–4) measure a patient's functional capacity, which directly influences whether intensive regimens are tolerable.
Organ function — renal, hepatic, and cardiac function tests establish safe dosing thresholds, particularly for nephrotoxic or cardiotoxic agents.
Prior treatment history — resistance patterns and cumulative prior toxicities narrow the available options in second- and third-line settings.
Genetic and biomarker data — BRCA mutation status, microsatellite instability (MSI), and tumor mutational burden (TMB) influence whether chemotherapy, targeted therapy, or a combination is preferred.

Enrollment in clinical trials is a recognized pathway when standard chemotherapy options have been exhausted or when investigational combinations may offer benefit, as governed by FDA Investigational New Drug (IND) regulations (21 CFR Part 312).

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)